Physician profile
Steven Ong
NPI 1225006349
$3,027.39
in general payments reported to CMS, 2019-2025
14 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $131 · 2021: $378 · 2022: $322 · 2023: $468 · 2024: $684 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.16 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $781.15 | 2019-2025 | Tavneos, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.60 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $457.60 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $442.46 | 2019-2022 | |
| Baxter Healthcare | $259.54 | 2019 | |
| Fresenius USA Marketing, INC. | $144.99 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.04 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $90.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.14 | 2021-2023 | Entyvio |
| Ardelyx, INC. | $34.65 | 2024 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $30.85 | 2024 | |
| Bard Peripheral Vascular, INC. | $26.04 | 2019 | |
| Travere Therapeutics, INC. | $24.20 | 2025 | |
| Akebia Therapeutics INC | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.